

SINAPPS

PPiP2 updates from Professor Belinda Lennox

At our recent trial management group meeting, we reviewed all the antibody results we have received from participants over the last couple of years. Our original study was restricted to recruiting people in the first 6 weeks of illness. When we moved to screening for SINAPPS2 we extended the length of current episode of illness up to 2 years, either at first episode or relapse. This was to try and make it easier for everyone to recruit.

However, as a result the prevalence of antibodies has gone down - from 8.8% to 5.1%. This means that the antibodies are more likely to be found in the blood at the beginning of the illness. It also means that with the current prevalence rate we are going to have to screen many more patients than we thought.

The other finding was that the patients who were positive for antibodies all had a very short duration of untreated psychosis (DUP) - on average a week. So they had a particular kind of illness, people who were feeling well one week, and who were then very unwell the next.


Taking these findings together I think we need to refocus our antibody testing: on people who have a sudden onset to their illness, and at the beginning of their illness - so people in early intervention services and on inpatient units, rather than other services.

This more focussed approach should increase the rate of antibody detection.

Thank you to all of you for your continued hard work in screening for SINAPPS2.


A very acute onset to illness in those with antibodies — need to refocus on this group

DUP = Duration of Untreated Psychosis



(unpublished data)

SINAPPS group studies overview (September 2016 - September 2018)



SINAPPS2 updates

We have exciting news about SINAPPS2. Yet another participant started with the trial treatment in October.

With the increasing recruitment at many PPIp2 sites over the last couple of months, more PPIp2 participants with anti-neuronal membrane antibodies were identified.

Since the summer we approached six antibody positive patients, and three of them were screened to take part in SINAPPS2. We are excited about positive developments in SINAPPS2 and we are looking forward to offering participation in the trial to more participants in coming months. The more patients we screen for antibodies in PPIp2, more likely we will identify potential SINAPPS2 participants. Let's keep it up!

PPIp2 recruiter of the month

Another successful month for PPIp2! Everyone's effort is definitely visible, as PPIp2 figures look better for the third month in a row!

Among the many sites who did particularly well, two of them vied to the very end of the month for the title of top recruiter. In the end, it was the team from **Oxford Health NHS Foundation Trust** (Dr Belinda Lennox, Ceridwen Morgan, Rebecca Dean, Chris Millar, Lucy Desborough, Tahnee Marquardt, Sarah Hollingsworth, Sally-Anne Vincent, Anna Heinen, Sherin Varghese, Duncan Dudley-Hicks) who brought home the title! Well done Oxford!

A special mention goes to the **Norfolk & Suffolk NHS Foundation Trust** (Dr Gabriela Martyn, Dr Uju Ugochukwu, Leanne Groves), as this month Dr Martyn alone managed to keep the competition alive until the very end! Thank you Dr Martyn!

Will October offer just as much excitement? Stay with us to find out!

CONTACTS

London: rebecca.pollard@psych.ox.ac.uk
East of England and Midlands: giuliano.tomei@psych.ox.ac.uk
South West : sally-anne.vincent@psych.ox.ac.uk
Project management: ksenija.yeeles@psych.ox.ac.uk
Research administrator: mio.shimazaki@psych.ox.ac.uk

www.sinapps.org.uk

Follow us on [Facebook](#) and [Twitter](#)